Corvus Pharmaceuticals Inc (OQ:CRVS)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 863 Mitten Rd Ste 102
BURLINGAME CA 94010-1311
Tel: 1-650-9004522
Website: https://www.corvuspharma.com
IR: See website
<
Key People
Richard A. Miller
Chairman of the Board, President, Chief Executive Officer
Leiv Lea
Chief Financial Officer
William Benton Jones
Senior Vice President - Pharmaceutical Development
Business Overview
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor's ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company's third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Financial Overview
For the fiscal year ended 31 December 2023, Corvus Pharmaceuticals Inc revenues was not reported. Net loss decreased 35% to $27M. Lower net loss reflects Research and development - Balancing val decrease of 33% to $15.8M (expense), Loss from equity method investment decrease of 47% to $5.3M (expense), General and administrative - Balancing decrease of 15% to $5.5M (expense).
Employees: 28 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $60.14M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$23.26M as of Dec 31, 2023
Net annual income (TTM): -$27.03M as of Dec 31, 2023
Free cash flow (TTM): -$23.97M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 49,038,582 as of Mar 19, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.